Last week, Sandoz announced they are closing a number of generic product development centers around the world, including the Sandoz Development Centre near Mumbai.
A few items in this report caught our eye. First, this hat tip to the CRO industry:
While a pharma industry expert said the closure of the development centre would mean Sandoz may not be able to launch any new generic products in India going forward, Sandoz said its operations in the country will not be impacted in any way. “We absolutely will continue to launch new products through Sandoz in the future, India is a key market for our generics division as well as for Novartis. It is not necessary for a company to have its own development centre to do bioequivalence studies, those can be commissioned to any established Clinical Research Organisation.”
Having “established” CROs perform bioequivalence studies is certainly nothing new. But it’s interesting how Sandoz has decided that even in India, it’s more cost efficient to outsource instead of owning this capability internally.
Interestingly, India was not alone:
According to Shahani, the company has also closed several development centres in Latin America and the US. “This week, we already announced a significant reduction of one of our European centres,” he added.